Hepatitis B vaccine - Vaxine

Drug Profile

Hepatitis B vaccine - Vaxine

Alternative Names: Hepadvax™; PreS-HBsAg

Latest Information Update: 06 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaxine
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B

Highest Development Phases

  • Phase I/II Hepatitis B

Most Recent Events

  • 06 Feb 2017 Vaxine plans a phase I/II trial for Hepatitis B in Australia (NCT03038802)
  • 31 Jul 2013 Vaxine initiates a phase I trial for Hepatitis B (prevention) in Australia (NCT01951677)
  • 20 Apr 2010 Development of the Hepatitis B vaccine is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top